

25 February 2013

Proposal Relating to the Funding of Certain Pharmaceuticals in DHB Hospitals and in the Community

PHARMAC is seeking feedback on a proposal relating to the establishment of a nationally-consistent list of pharmaceuticals to be funded within DHB hospitals. This list would be published in Part II of Section H of the Pharmaceutical Schedule from 1 July 2013.

As a related issue, we are also seeking feedback on changes to the funding of some pharmaceuticals in the community: de-listings and changes to subsidy criteria, as a flow-on effect of this proposal.

This consultation refers to the creation of the final six therapeutic groups within Section H:

- Blood and Blood-Forming Organs (*haematology, intravenous fluids, vitamins and minerals*)
- Extemporaneous Compounds (*suspending agents, solvents and active ingredients in powder form*)
- Oncology Agents and Immunosuppressants (*oncology, haematology, transplant medicine*)
- Special Foods (*oral and enteral nutrition*)
- Vaccines
- Various (*antidotes, diagnostic agents, surgical preparations*)

While these headings primarily relate to pharmaceuticals that are used for the purposes indicated above, this is not always the case. As such, while we have distributed this proposal widely, if you consider that there are organisations or individuals that should be made aware of this document, please refer them to this consultation, or let us know.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Thursday, 28 March 2013** to:

Sean Dougherty
Funding Systems Development Manager
PHARMAC
PO Box 10 254
Wellington 6143

Email: sean.dougherty@pharmac.govt.nz

Fax: 04 460 4995

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do. If you would like us to withhold any commercially sensitive, confidential

proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like withheld.

If you have any questions about certain products, or would like to arrange a meeting or teleconference to discuss this proposal further, please contact either Sean Dougherty, or:

For the Blood and Blood-Forming Organs and Oncology Agents and Immunosuppressants therapeutic groups:

Sue Anne Yee
Therapeutic Group Manager
sueanne.yee@pharmac.govt.nz

For the Extemporaneous Compounds and Vaccines therapeutic groups:

Greg Williams
Senior Therapeutic Group Manager
greg.williams@pharmac.govt.nz

For the Special Foods and Various therapeutic groups:

Natalie Davis
Therapeutic Group Manager
natalie.davis@pharmac.govt.nz

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

We are interested in all feedback relevant to this proposal. However, we are particularly interested in DHB hospitals identifying significant clinical, financial or workflow issues that may arise from parts of this proposal.

Other consultations

This document contains the fourth and final section of products that are proposed as inclusions and exclusions from Section H. All of PHARMAC's previous consultations relevant to this work are available on PHARMAC's website:

www.pharmac.govt.nz/HospitalPharmaceuticals

Background

Following the Government's decision that PHARMAC should become responsible for the funding of hospital pharmaceuticals, we have reviewed the use of hospital pharmaceuticals with a view to creating a nationally-consistent list of pharmaceuticals that would be funded in all DHB hospitals. Our intention is that this list would be contained in Part II of Section H of the Pharmaceutical Schedule. Use of pharmaceuticals outside of the list in Section H, or outside of any specified indication restrictions contained in the list, would require approval under a case-by-case exceptions mechanism.

Please note that we released a consultation titled "Proposed Pharmaceutical Schedule Rules for Hospital Pharmaceuticals" in July last year which may provide some useful context for reviewing these lists. This consultation (which closed on 31 August 2012) is still available on our website: www.pharmac.govt.nz/HospitalPharmaceuticals. In summary we have proposed that:

- Products included in Part II of Section H would be available for use in all DHB hospitals.
- Restrictions on use, either prescriber-type or indication-based restrictions would apply to some products. Detail as to how these might be implemented is provided.
- Use of products outside the list, or for use outside any indication-based restrictions, would require case-by-case approval under a scheme that we expect to be based on PHARMAC's Named Patient Pharmaceutical Assessment policy. An outline of how this might be implemented differently in DHB hospitals is provided.

The process leading up to a decision on the products to be included in each therapeutic group involves three distinct stages: information collection, clinical advice and consultation. We began by requesting information on the current use of pharmaceuticals in all DHB hospitals and, augmenting this with information provided by relevant professional societies, sought advice from the Pharmacology and Therapeutics Advisory Committee (PTAC), along with its Cardiovascular, Haematology, Cancer Treatments, Transplant Immunosuppressants, Special Foods and Hospital Pharmaceuticals Subcommittees.

Minutes of PTAC and PTAC Subcommittee meetings that are relevant to this proposal are available on our website: www.pharmac.govt.nz/HospitalPharmaceuticals

Details of the proposal

We are proposing to create a list of pharmaceuticals that would be available in all DHB hospitals. The list would be in Section H of the Pharmaceutical Schedule and would use the "therapeutic group" structure that is used in the Pharmaceutical Schedule for community pharmaceuticals (Section B), which is broadly based on the anatomical-therapeutic-chemical (ATC) classification system used by the World Health Organisation. This proposal relates to the list of pharmaceuticals for five of these therapeutic groups: the Blood and Blood-Forming Organs group, the Extemporaneous Compounds group, the Oncology Agents and Immunosuppressants group, the Special Foods group, the Vaccines group and the Various group.

Appended to this letter are the lists of pharmaceuticals that are proposed for inclusion in Section H under the five therapeutic groups, along with any proposed prescribing restrictions. These appendices also contain details of products that were also considered, but that we are not proposing to include in Section H at this time.

Please note that:

- if a pharmaceutical does not appear in these appendices, it will be for one of two reasons: first, that it was not considered through this process; or second, that it has already been considered as part of another therapeutic group and so was the subject of an earlier round of consultation;
- some chemicals will have formulations listed across several sections – for example, low-dose aspirin would be included as part of the antithrombotic agents section (in the Blood and Blood-Forming Organs therapeutic group), and high dose preparations would be listed as analgesic agents (in the Nervous System therapeutic group); and
- for a very small number of products, we will address different indications at different times but we will be clear when this is the case, and we expect that this will only be the case for biologic agents.

If you think that a product has been omitted from this process that should not have been, please let us know.

Pharmaceuticals not included

The appendices to this letter also detail the pharmaceuticals that we are proposing would be excluded from Part II of Section H at this time. In general, these fall into three categories:

1. Products for which we are of the view that inclusion in Section H should only occur if they become subsidised in the community.
2. Products that have been used in some DHB hospitals, but are not widely used and/or we consider that there is insufficient need for them to be available.
3. Products that are not currently used in DHB hospitals, and we consider that a substantive funding application for these would need to be considered (and in some cases Medsafe registration is yet to be obtained).

Please note however that if the proposal is accepted, and these products are excluded, any of them could be re-considered for inclusion in Section H at any time in the future, through our normal process for considering applications for funding.

Community listings

Should this proposal be accepted, we would also list some of these pharmaceuticals in Section B of the Pharmaceutical Schedule, which would mean that they would be subsidised when dispensed from community pharmacies. We are also proposing to make an amendment to the prescribing criteria of one of these items in the community, which would create better alignment of use between hospitals and the community.

These proposed changes are highlighted in the attached appendices.

BLOOD AND BLOOD FORMING ORGANS

Antianaemics

Hypoplastic and Haemolytic

Restricted

Must meet community Special Authority criteria

ERYTHROPOIETIN ALPHA

- Inj 1,000 iu per 0.5 ml syringe
- Inj 2,000 iu per 0.5 ml syringe
- Inj 3,000 iu per 0.3 ml syringe
- Inj 4,000 iu per 0.4 ml syringe
- Inj 5,000 iu per 0.5 ml syringe
- Inj 6,000 iu per 0.6 ml syringe
- Inj 10,000 iu per 1 ml syringe

ERYTHROPOIETIN BETA

- Inj 2,000 iu per 0.3 ml syringe
- Inj 3,000 iu per 0.3 ml syringe
- Inj 4,000 iu per 0.3 ml syringe
- Inj 5,000 iu per 0.3 ml syringe
- Inj 6,000 iu per 0.3 ml syringe
- Inj 10,000 iu per 0.6 ml syringe

Megaloblastic

FOLIC ACID

- Oral liq 50 mcg per ml
- Tab 0.8 mg
- Tab 5 mg
- Inj 5 mg per ml, 10 ml vial

Antifibrinolytics, Haemostatics and Local Sclerosants

FERRIC SUBSULFATE

- Soln 500 ml
- Gel 25.9%, 8 g

SODIUM TETRADECYL SULPHATE

- Inj 3%, 2 ml ampoule

TRANEXAMIC ACID

- Tab 500 mg
- Inj 500 mg per 5 ml ampoule

Blood Factors

EPTACOG ALFA (RECOMBINANT FACTOR VIIA)

- Inj 1 mg vial
- Inj 2 mg vial
- Inj 5 mg vial

MOROCTOCOG ALFA (RECOMBINANT FACTOR VIII)

- Inj 250 iu vial
- Inj 500 iu vial
- Inj 1,000 iu vial
- Inj 2,000 iu vial

NONACOG ALFA (RECOMBINANT FACTOR IX)

- Inj 250 iu vial
- Inj 500 iu vial
- Inj 1,000 iu vial
- Inj 2,000 iu vial

OCTOCOG ALFA (RECOMBINANT FACTOR VIII)

- Inj 250 iu vial
- Inj 500 iu vial
- Inj 1,000 iu vial
- Inj 1,500 iu vial
- Inj 2,000 iu vial
- Inj 3,000 iu vial

Vitamin K

PHYTOMENADIONE

- Inj 2 mg per 0.2 ml ampoule
- Inj 10 mg per ml, 1 ml ampoule

Antithrombotics

Anticoagulants

BIVALIRUDIN

Restricted

Either:

1. *For use in heparin-induced thrombocytopenia; or*
2. *For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.*

- Inj 250 mg vial

DABIGATRAN

- Cap 75 mg
- Cap 110 mg
- Cap 150 mg

DALTEPARIN

- Inj 2,500 iu in 0.2 ml syringe
- Inj 5,000 iu in 0.2 ml syringe
- Inj 7,500 iu in 0.75 ml syringe
- Inj 10,000 iu in 1 ml syringe
- Inj 10,000 iu in 0.4 ml syringe
- Inj 12,500 iu in 0.5 ml syringe
- Inj 15,000 iu in 0.6 ml syringe
- Inj 18,000 iu in 0.72 ml syringe

DANAPAROID

Restricted

For use in heparin-induced thrombocytopenia

- Inj 750 u in 0.6 ml ampoule

DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]

- Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag

ENOXAPARIN

- Inj 20 mg in 0.2 ml syringe
- Inj 40 mg in 0.4 ml syringe
- Inj 40 mg in 0.4 ml ampoule
- Inj 60 mg in 0.6 ml syringe

Inj 80 mg in 0.8 ml syringe
Inj 100 mg in 1 ml syringe
Inj 120 mg in 0.8 ml syringe
Inj 150 mg in 1 ml syringe

FONDAPARINUX SODIUM

Restricted

For use in heparin-induced thrombocytopenia

Inj 2.5 mg in 0.5 ml syringe
Inj 7.5 mg in 0.6 ml syringe

HEPARIN SODIUM

Inj 100 iu per ml, 250 ml bag
Inj 1,000 iu per ml, 1 ml ampoule
Inj 1,000 iu per ml, 5 ml ampoule
Inj 1,000 iu per ml, 35 ml ampoule
Inj 5,000 iu per ml, 1 ml ampoule
Inj 5,000 iu per ml, 5 ml ampoule
Inj 5,000 iu in 0.2 ml ampoule

HEPARINISED SALINE

Inj 10 iu per ml, 5 ml ampoule
Inj 100 iu per ml, 2 ml ampoule
Inj 100 iu per ml, 5 ml ampoule

PHENINDIONE

Tab 10 mg
Tab 25 mg
Tab 50 mg

PROTAMINE SULPHATE

Inj 10 mg per ml, 5 ml ampoule

RIVAROXABAN

Restricted

Must meet community Special Authority criteria

Tab 10 mg

WARFARIN SODIUM

Tab 1 mg
Tab 2 mg
Tab 3 mg

Tab 5 mg

Antiplatelets

ABCIXIMAB

Restricted

For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention

Inj 10 mg per 5 ml vial

ASPIRIN

Tab 100 mg
Suppos 300 mg

CLOPIDOGREL

Tab 75 mg

DIPYRIDAMOLE

Tab 25 mg
Tab long-acting 150 mg
Inj 5 mg per ml, 2 ml ampoule

EPTIFIBATIDE

Restricted

For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention

Inj 750 mcg per ml, 100 ml vial
Inj 2 mg per ml, 10 ml vial

PRASUGREL

Restricted

Either:

- Use as per the community Special Authority criteria; or*
- For short term (maximum 7 days) use while in hospital following ST-elevated myocardial infarction.*

Tab 5 mg
Tab 10 mg

TICLOPIDINE

Tab 250 mg

Fibrinolytic agents

ALTEPLASE

Inj 10 mg vial
Inj 50 mg vial

STREPTOKINASE

Inj 250,000 iu vial
Inj 1,500,000 iu vial

TENECTEPLASE

Inj 50 mg vial

UROKINASE

Inj 10,000 iu vial
Inj 50,000 iu vial
Inj 100,000 iu vial
Inj 500,000 iu vial

Colony-Stimulating Factors

Granulocyte Colony-Stimulating Factors

FILGRASTIM

Restricted – *oncologist or haematologist*

Inj 300 mcg in 1 ml vial
Inj 300 mcg in 0.5 ml syringe
Inj 480 mcg in 0.5 ml syringe

Fluids and Electrolytes

Intravenous Administration

CALCIUM CHLORIDE

Inj 100 mg per ml, 10 ml vial

COMPOUND ELECTROLYTES

Inj sodium 140 mmol/L with potassium 5 mmol/L, magnesium 1.5 mmol/L, chloride 98 mmol/L, acetate 27 mmol/L and gluconate 23 mmol/l, 500 ml bag **{Plasma-Lyte 148 in Water}**
Inj sodium 140 mmol/L with potassium 5 mmol/L, magnesium 1.5 mmol/L, chloride 98 mmol/L, acetate 27 mmol/L and gluconate 23 mmol/l, 1,000 ml bag **{Plasma-Lyte 148 in Water}**

COMPOUND ELECTROLYTES WITH GLUCOSE

Inj glucose 50 g with 140 mmol sodium, 5 mmol potassium, 1.5 mmol magnesium, 98 mmol chloride, 27 mmol acetate and 23 mmol gluconate, 1,000 ml bag
{*Plasma-Lyte 148 in Glucose*}

COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]

Inj sodium 131 mmol/L with potassium 5 mmol/L, calcium 2 mmol/L, bicarbonate 29 mmol/L, chloride 111 mmol/L, 500 ml bag

Inj sodium 131 mmol/L with potassium 5 mmol/L, calcium 2 mmol/L, bicarbonate 29 mmol/L, chloride 111 mmol/L, 1,000 ml bag

COMPOUND SODIUM LACTATE WITH GLUCOSE

Inj sodium 131 mmol/L with potassium 5 mmol/L, calcium 2 mmol/L, bicarbonate 29 mmol/L, chloride 111 mmol/L and glucose 5%, 1,000 ml bag

GLUCOSE

Inj 5%, 50 ml bag
Inj 5%, 100 ml bag
Inj 5%, 250 ml bag
Inj 5%, 500 ml bag
Inj 5%, 1,000 ml bag
Inj 10%, 500 ml bag
Inj 10%, 1,000 ml bag
Inj 50%, 10 ml ampoule
Inj 50%, 90 ml bottle
Inj 50%, 500 ml bag
Inj 70%, 500 ml bag
Inj 70%, 1,000 ml bag

GLUCOSE WITH POTASSIUM CHLORIDE

Inj 5% glucose with 20 mmol/L potassium chloride, 1,000 ml bag

GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE

Inj 4% glucose with potassium chloride 20 mmol/L and sodium chloride 0.18%, 1,000 ml bag

Inj 4% glucose with potassium chloride 30 mmol/L and sodium chloride 0.18%, 1,000 ml bag

GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE

Inj 10% glucose with potassium chloride 10 mmol and sodium chloride 15 mmol, 500 ml bag

GLUCOSE WITH SODIUM CHLORIDE

Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag

Inj glucose 5% with sodium chloride 0.2%, 500 ml bag

Inj glucose 5% with sodium chloride 0.45%, 1000 ml bag

POTASSIUM CHLORIDE

Inj 75 mg (1 mmol) per ml, 10 ml ampoule

Inj 225 mg (3 mmol) per ml, 20 ml ampoule

POTASSIUM CHLORIDE WITH SODIUM CHLORIDE

Inj 20 mmol/L potassium chloride with 0.9% sodium chloride, 1,000 ml bag

Inj 30 mmol/L potassium chloride with 0.9% sodium chloride, 1,000 ml bag

Inj 40 mmol/L potassium chloride with 0.9% sodium chloride, 1,000 ml bag

POTASSIUM DIHYDROGEN PHOSPHATE

Inj 1 mmol per ml, 10 ml ampoule

RINGER'S SOLUTION

Inj sodium 147 mmol/L with potassium 4 mmol/L, calcium 2.2 mmol/L, chloride 156 mmol/L, 1,000 ml bag

SODIUM ACETATE

Inj 4 mmol per ml, 20 ml ampoule

SODIUM BICARBONATE

Inj 8.4%, 10 ml vial

Inj 8.4%, 50 ml vial

Inj 8.4%, 100 ml vial

SODIUM CHLORIDE

Inj 0.45%, 500 ml bag

Inj 0.9%, 5 ml ampoule

Inj 0.9%, 10 ml ampoule

Inj 0.9%, 20 ml ampoule

Inj 0.9%, 50 ml bag

Inj 0.9%, 100 ml bag

Inj 0.9%, 250 ml bag

Inj 0.9%, 500 ml bag

Inj 0.9%, 1,000 ml bag

Inj 1.8%, 500 ml bottle

Inj 3%, 1,000 ml bag

Inj 23.4% (4 mmol/ml), 20 ml

SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]

Inj 1 mmol per ml, 20 ml ampoule

WATER

Inj 5 ml ampoule

Inj 10 ml ampoule

Inj 20 ml ampoule

Inj 250 ml bag

Inj 500 ml bag

Inj 1,000 ml bag

Oral Administration**CALCIUM POLYSTYRENE SULPHONATE**

Powder

COMPOUND ELECTROLYTES

Powder for oral soln

COMPOUND ELECTROLYTES WITH GLUCOSE

Soln with electrolytes

POTASSIUM BICARBONATE

Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg

POTASSIUM CHLORIDE

Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)

Tab long-acting 600 mg (8 mmol)

Oral liq 2 mmol/ml 25 ml

SODIUM BICARBONATE

Cap 840 mg

SODIUM CHLORIDE

Tab 600 mg

Oral liq 2 mmol/ml 25 ml

SODIUM POLYSTYRENE SULPHONATE

Powder

GLUCOSE

Gel 40%

Tab 1.5 mg

Powder

Plasma Volume Expanders**GELATINE, SUCCINYLATED**

Inj 4%, 500 ml bag

{*Gelofusine / Gelofusal*}

HYDROXYETHYL STARCH 130/0.4 WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE AND SODIUM CHLORIDE

Inj 6% with magnesium chloride 0.03%, potassium chloride 0.03%, sodium acetate 0.463% and sodium chloride 0.6%, 500 ml bag

{*Volulyte*}

HYDROXYETHYL STARCH 130/0.4 WITH SODIUM CHLORIDE

Inj 6% with sodium chloride 0.9%, 500 ml bag

{*Voluven*}

Minerals**Calcium****CALCIUM CARBONATE**

Tab 1.25 g (500 mg elemental)

Tab 1.5 g (600 mg elemental)

Tab eff 1.75 g (1 g elemental)

CALCIUM GLUCONATE

Inj 10%, 10 ml

Fluoride**SODIUM FLUORIDE**

Tab 1.1 mg

Iron**FERROUS FUMARATE**

Tab 200 mg

FERROUS FUMARATE WITH FOLIC ACID

Tab 310 mg with folic acid 350 mcg

FERROUS GLUCONATE WITH ASCORBIC ACID

Tab 170 mg with ascorbic acid 40 mg

FERROUS SULPHATE

Oral liq 150 mg per 5 ml

Tab long-acting 325 mg

FERROUS SULPHATE WITH ASCORBIC ACID

Tab long-acting 325 mg with ascorbic acid 500 mg

FERROUS SULPHATE WITH FOLIC ACID

Tab long-acting 325 mg with folic acid 350 mcg

IRON POLYMALTOSE

Inj 50 mg per ml, 2 ml ampoule

IRON SUCROSE

Inj 20 mg per ml, 5 ml ampoule

Magnesium**MAGNESIUM SULPHATE**

Inj 0.4 mmol per ml, 250 ml bag

Inj 2 mmol per ml (49.3%), 5 ml ampoule

Zinc**ZINC CHLORIDE**

Inj 5.3 mg per ml, 2 ml ampoule

ZINC SULPHATE

Cap 220 mg (50 mg elemental)

Vitamins**Vitamin A****RETINOL**

Tab 10,000 iu

Cap 25,000 iu

Inj 150,000 iu per ml, 7.5 ml

Vitamin B**HYDROXOCOBALAMIN ACETATE**

Inj 1 mg per ml, 1 ml ampoule

PYRIDOXINE HYDROCHLORIDE

Tab 25 mg

Tab 50 mg

Inj 100 mg per ml, 1 ml ampoule

THIAMINE HYDROCHLORIDE

Tab 50 mg

Tab 100 mg

Inj 100 mg per ml, 2 ml vial

VITAMIN B COMPLEX

Tab, strong, BPC

Vitamin C**ASCORBIC ACID**

Tab 100 mg

Tab chewable 250 mg

Powder

Vitamin D**ALFACALCIDOL**

Cap 0.25 mcg

Cap 1 mcg

Oral drops 2 mcg per ml

CALCITRIOL

Cap 0.25 mcg

Cap 0.5 mcg

Oral liq 1 mcg per ml

CHOLECALCIFEROL

Tab 1.25 mg (50,000 iu)

Multivitamin Preparations

MULTIVITAMINS

Restricted (cap and powder)

Must meet community Special Authority criteria

Cap vitamin A 2500 units, betacarotene 3 mg, cholecalciferol 11 mcg, alpha tocopherol 150 units, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg [**vitABDECK**]

Tab (BPC cap strength)

Powder vitamin A 4200 mcg, 55.5 mcg vitamin D1, 21.4 mg vitamin E, 400 mg vitamin C, 166 mcg vitamin K1, 3.2 mg thiamin, 4.4 mg riboflavin, 35 mg niacin, 3.4 mg vitamin B6, 303 mcg folic acid, 8.6 mcg vitamin B12, 214 mcg biotin, 17 mg pantothenic acid, 350 mg choline and 700 mg inositol [**Paediatric Seravit**]

Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1) [**Pabrinex IM**]

Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1) [**Pabrinex IV**]

Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1) [**Pabrinex IV**]

VITAMIN A WITH VITAMINS D AND C

Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops

Products proposed not to be included

The following products were considered as part of the review of this section, and we are proposing that they not be listed in Part II of Section H at this time. Please note that this would not prevent them from being considered for inclusion at a later date.

Alpha tocopheryl acetate
Ancestim
Argatroban
Dextran 40 in glucose
Dextran 40 in sodium chloride
Dextran 70 in glucose
Dextran 70 in sodium chloride
Ergocalciferol
Ethanalamine oleate
Hydroxyethyl starch 200/0.5
Lenograstim
Lepirudin
Magnesium chloride
Menadiol phosphate
Ornipressin
Pegfilgrastim
Polidocanol
Polygeline
Potassium acetate
Retepase
Sargramostim
Sodium hydrogen phosphate

Tinzaparin

Tirofiban

We are also proposing that the following products not be included. Please note that for each of these, we are proposing that other presentations or strengths would be included in this section.

Alfacalcidol

Inj 2 mg

Ascorbic acid

Tab chewable 500 mg

Tab chewable 1 g

Inj 500 mg per 5 ml

Aspirin

Tab 75 mg

Tab 150 mg

Calcitriol

Inj 1 mcg

Compound electrolytes

Inj glucose 50 g with 40 mmol sodium, 13 mmol potassium, 1.5 mmol magnesium, 40 mmol chloride and 16 mmol acetate, 1,000 ml **{Plasma-Lyte 56 in Glucose}**

Ice block 62.5 ml **{Hydralyte}**

Glucose

Inj 5%, 10 ml

Inj 25%, 1,000 ml

Inj 50%, 50 ml syringe

Glucose with potassium chloride and sodium chloride

Inj 2.5% with potassium chloride 20 mmol/L and sodium chloride 0.45%, 500 ml

Inj 4% with potassium chloride 20 mmol/L and sodium chloride 0.18%, 500 ml

Glucose with sodium chloride

Inj 4% with sodium chloride 0.18%, 500 ml

Inj 4% with sodium chloride 0.18%, 1,000 ml

Inj 5% with sodium chloride 0.45%, 500 ml

Heparin sodium

Inj 50 mg per ml, 500 ml

Phytomenadione

Tab 10 mg

Potassium chloride

Inj 150 mg (2 mmol) per ml, 10 ml

Pyridoxine

Inj 50 mg

Retinol

Cap 9,000 iu

Sodium bicarbonate

Inj 5%, 500 ml

Inj 8.4%, 50 ml syringe

Sodium tetradecyl sulphate

Inj 0.5%, 2 ml

Inj 1%, 2 ml

Thiamine

Cap 100 mg

Water

Inj 100 ml

Some of these products are currently included in Part II of Section H, because PHARMAC has established national pricing contracts for them. As part of this proposal PHARMAC would delist the following products from Section H with effect from 1 July 2013:

Dextran 70 with sodium chloride, inf 6% with 0.9% sodium chloride (Baxter)

Gelatin plasma replacer, inf 3.5%, 500 ml bag (Haemaccel)

Heparin with sodium chloride, inf 25,000 iu with 0.9% sodium chloride; 500 ml (Baxter)

Pegfilgrastim, inj 6 mg per 0.6 ml prefilled syringe (Neulastim)

Potassium chloride with glucose and sodium chloride, inf 20 mmol/l with 2.5% glucose and 0.45% sodium chloride (Baxter)

Sodium bicarbonate, inf 5% (Baxter)

Sodium chloride with glucose, inf 0.18% with glucose 4% (Baxter)

Sodium chloride with glucose, inf 0.45% with glucose 5%; 500 ml (Baxter)

Tirofiban hydrochloride, inj 0.25 mg per ml, 50 ml (Aggrastat)

Alpha tocopheryl acetate

Alpha tocopheryl acetate is not currently listed in the community Schedule, but has been funded through NPPA since the funded version (Micelle E) was discontinued in 2011. We expect to issue further consultation in the coming months relating to funding of this agent.

Pegfilgrastim

We are not proposing that pegfilgrastim be included in Section H at this time. We are working through this issue with the supplier of pegfilgrastim and may release further consultation on this topic at a late time.

Sargramostim

This proposal also does not include the listing of sargramostim, which we are aware is used in paediatric oncology. We are still considering a number of funding changes relating to cancer treatments (as noted in the Oncology Agents and Immunosuppressants section) and expect to be consulting on this separately in the near future.

Sodium tetradecyl sulphate

We are proposing that the 3% strength of sodium tetradecyl sulphate be included in Section H, but not the 0.5% or 1% strengths. All three strengths are currently subsidised in the community, and as part of this proposal, we are proposing that the 0.5% and 1% strengths would also be delisted from the community Schedule from 1 October 2013. We note that the majority of use of this agent in the community is for the 3% strength.

EXTEMPORANEOUS COMPOUNDS

Extemporaneous Compounds

ACETIC ACID

Liquid

ALUM

Powder BP

ARACHIS OIL [PEANUT OIL]

Liquid

ASCORBIC ACID

Powder

BENZOIN

Tincture compound BP

BISMUTH SUBGALLATE

Powder

BORIC ACID

Powder

CARBOXYMETHYLCELLULOSE

Soln 1.5%

CETRIMIDE

Soln 40%

CHLOROFORM

Chloroform BP

CITRIC ACID

Powder BP

CLOVE OIL

Liquid

COAL TAR

Soln BP

CODEINE PHOSPHATE

Powder

COLLODION FLEXIBLE

Liquid

COMPOUND HYDROXYBENZOATE

Soln

CYSTEAMINE HYDROCHLORIDE

Powder

DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE

Inj 37.46 mg with sodium dihydrogen phosphate
47.7 mg in 1.5 ml ampoule *{Amphotericin
Buffer Solution}*

DITHRANOL

Powder

GLYCERIN WITH SODIUM SACCHARIN

Suspension *{Ora-Sweet SF}*

GLYCERIN WITH SUCROSE

Suspension *{Ora-Sweet}*

GLYCEROL

Liquid

HYDROCORTISONE

Powder

LACTOSE

Powder

MAGNESIUM HYDROXIDE

Paste

MENTHOL

Crystals

METHADONE HYDROCHLORIDE

Powder

METHYL HYDROXYBENZOATE

Powder

METHYLCELLULOSE

Powder

Suspension *{Ora-Plus}*

METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN

Suspension *{Ora-Blend SF}*

METHYLCELLULOSE WITH GLYCERIN AND SUCROSE

Suspension *{Ora-Blend}*

OLIVE OIL

Liquid

PARAFFIN

Liquid

PHENOBARBITONE SODIUM

Powder

PHENOL

Liquid

PILOCARPINE NITRATE

Powder

POLYHEXAMETHYLENE BIGUANIDE

Liquid

PROPYLENE GLYCOL

Liquid

SALICYLIC ACID

Powder

SILVER NITRATE

Crystals

SODIUM BICARBONATE

Powder BP

SODIUM CITRATE

Powder

SODIUM METABISULFITE

Powder

STARCH

Powder

SULPHUR

Precipitated

Sublimed

SYRUP (PHARMACEUTICAL GRADE)

Liquid

TRICHLORACETIC ACID

Granules

TRI-SODIUM CITRATE

Crystals

UREA

Powder BP

WOOL FAT

Oint, anhydrous

XANTHAMGum 1% *{Diluent A}***ZINC OXIDE**

Powder

Products proposed not to be included

The following products were considered as part of the review of this section, and we are proposing that they not be listed in Part II of Section H at this time. Please note that this would not prevent them from being considered for inclusion at a later date.

Acetone

Liquid

Almond oil

Liquid

Anise oil

Liquid

Aspirin

Powder

Carboxymethylcellulose with propylene glycol

Gel

Diethyl ether

Liquid

Eucalyptus oi

Liquid

Ichthammol

Liquid

Isopropyl alcohol

Liquid

Lavender oil

Liquid

Magnesium carbonate

Powder

Ointment base, greasy

Oint

Paracetamol

Powder

Potassium bromide

Powder

Povidone K30

Powder

Trichloroethane

Soln

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Chemotherapeutic Agents

Alkylating Agents

BUSULFAN

Tab 2 mg
Inj 6 mg per ml, 10 ml ampoule

CARMUSTINE

Inj 100 mg vial

CHLORAMBUCIL

Tab 2 mg

CYCLOPHOSPHAMIDE

Tab 50 mg
Inj 1 g vial
Inj 2 g vial

IFOSFAMIDE

Inj 1 g vial
Inj 2 g vial

LOMUSTINE

Cap 10 mg
Cap 40 mg

MELPHALAN

Tab 2 mg
Inj 50 mg vial

THIOTEPA

Inj 15 mg vial

Anthracyclines and Other Cytotoxic Antibiotics

BLEOMYCIN SULPHATE

Inj 15,000 iu (10 mg) vial

DACTINOMYCIN [ACTINOMYCIN D]

Inj 0.5 mg vial

DAUNORUBICIN

Inj 2 mg per ml, 10 ml vial

DOXORUBICIN HYDROCHLORIDE

Inj 2 mg per ml, 5 ml vial
Inj 2 mg per ml, 25 ml vial
Inj 2 mg per ml, 50 ml vial
Inj 2 mg per ml, 100 ml vial

EPIRUBICIN HYDROCHLORIDE

Inj 2 mg per ml, 5 ml vial
Inj 2 mg per ml, 25 ml vial
Inj 2 mg per ml, 50 ml vial
Inj 2 mg per ml, 100 ml vial

IDARUBICIN HYDROCHLORIDE

Cap 5 mg
Cap 10 mg
Inj 5 mg vial
Inj 10 mg vial

MITOMYCIN

Inj 5 mg vial

MITOZANTRONE

Inj 2 mg per ml, 5 ml vial
Inj 2 mg per ml, 10 ml vial
Inj 2 mg per ml, 12.5 ml vial

Antimetabolites

CAPECITABINE

Tab 150 mg
Tab 500 mg

CLADRIBINE

Inj 1 mg per ml, 10 ml vial
Inj 2 mg per ml, 5 ml vial

CYTARABINE

Inj 20 mg per ml, 5 ml vial
Inj 200 mg per ml, 25 ml vial
Inj 100 mg per ml, 10 ml vial
Inj 100 mg per ml, 20 ml vial

FLUDARABINE PHOSPHATE

Tab 10 mg
Inj 50 mg vial

FLUOROURACIL

Inj 25 mg per ml, 100 ml vial
Inj 50 mg per ml, 10 ml vial
Inj 50 mg per ml, 20 ml vial
Inj 50 mg per ml, 50 ml vial
Inj 50 mg per ml, 100 ml vial

GEMCITABINE

Inj 10 mg per ml, 20 ml vial
Inj 10 mg per ml, 100 ml vial
Inj 200 mg vial
Inj 1 g vial

IRINOTECAN HYDROCHLORIDE

Inj 20 mg per ml, 2 ml vial
Inj 20 mg per ml, 5 ml vial

MERCAPTOPURINE

Tab 50 mg

METHOTREXATE

Tab 2.5 mg
Tab 10 mg
Inj 2.5 mg per ml, 2 ml vial
Inj 25 mg per ml, 2 ml vial
Inj 25 mg per ml, 20 ml vial
Inj 100 mg per ml, 10 ml vial
Inj 100 mg per ml, 50 ml vial

THIOGUANINE

Tab 40 mg

Other Cytotoxic Agents

AMSACRINE

Inj 50 mg per ml, 1.5 ml ampoule

ANAGRELIDE HYDROCHLORIDE

Cap 0.5 mg

ARSENIC TRIOXIDE

Inj 1 mg per ml, 10 ml vial

BORTEZOMIB**Restricted***Must meet PCT Special Authority criteria*

Inj 1 mg vial

Inj 3.5 mg vial

COLASPASE [L-ASPARAGINASE]

Inj 10,000 iu vial

DACARBAZINE

Inj 200 mg vial

ETOPOSIDE

Cap 50 mg

Cap 100 mg

Inj 20 mg per ml, 5 ml vial

ETOPOSIDE (AS PHOSPHATE)

Inj 100 mg vial

HYDROXYUREA

Cap 500 mg

PEGASPARGASE**Restricted***Must meet PCT Special Authority criteria*

Inj 750 iu per ml, 5 ml vial

PENTOSTATIN [DEOXYCOFORMYCIN]

Inj 10 mg vial

PROCARBAZINE HYDROCHLORIDE

Cap 50 mg

TEMOZOLOMIDE**Restricted***Must meet community Special Authority criteria*

Cap 5 mg

Cap 20 mg

Cap 100 mg

Cap 250 mg

THALIDOMIDE**Restricted***Either:*

1. For use in accordance with the PCT Special Authority criteria; or
2. For the treatment of erythema nodosum leprosum

Cap 50 mg

Cap 100 mg

TRETINOIN

Cap 10 mg

Platinum Compounds**CARBOPLATIN**

Inj 10 mg per ml, 5 ml vial

Inj 10 mg per ml, 15 ml vial

Inj 10 mg per ml, 45 ml vial

Inj 10 mg per ml, 100 ml vial

CISPLATIN

Inj 1 mg per ml, 50 ml vial

Inj 1 mg per ml, 100 ml vial

OXALIPLATIN

Inj 50 mg vial

Inj 100 mg vial

Protein-Tyrosine Kinase Inhibitors**DASATINIB****Restricted***Must meet community Special Authority criteria*

Tab 20 mg

Tab 50 mg

Tab 70 mg

Tab 100 mg

ERLOTINIB**Restricted***Must meet community Special Authority criteria*

Tab 100 mg

Tab 150 mg

IMATINIB**Restricted***Must meet community Special Authority criteria*

Tab 100 mg

LAPATINIB**Restricted***Must meet community Special Authority criteria*

Tab 250 mg

PAZOPANIB**Restricted***Must meet community Special Authority criteria*

Tab 200 mg

Tab 400 mg

SUNITINIB**Restricted***Must meet community Special Authority criteria*

Cap 12.5 mg

Cap 25 mg

Cap 50 mg

Taxanes**DOCETAXEL**

Inj 10 mg per ml, 2 ml vial

Inj 10 mg per ml, 8 ml vial

PACLITAXEL

Inj 6 mg per ml, 5 ml vial

Inj 6 mg per ml, 16.7 ml vial

Inj 6 mg per ml, 25 ml vial

Inj 6 mg per ml, 50 ml vial

Inj 6 mg per ml, 100 ml vial

Treatment of Cytotoxic-Induced Side-Effects**CALCIUM FOLINATE**

- Tab 15 mg
- Inj 3 mg per ml, 1 ml ampoule
- Inj 10 mg per ml, 5 ml ampoule
- Inj 10 mg per ml, 10 ml vial
- Inj 10 mg per ml, 30 ml vial
- Inj 10 mg per ml, 100 ml vial

MESNA

- Tab 400 mg
- Tab 600 mg
- Inj 100 mg per ml, 4 ml ampoule
- Inj 100 mg per ml, 10 ml ampoule

Vinca Alkaloids**VINBLASTINE SULPHATE**

- Inj 1 mg per ml, 10 ml vial

VINCRISTINE SULPHATE

- Inj 1 mg per ml, 1 ml vial
- Inj 1 mg per ml, 2 ml vial

VINORELBINE

- Inj 10 mg per ml, 1 ml vial
- Inj 10 mg per ml, 5 ml vial

Endocrine Therapy**BICALUTAMIDE****Restricted***Must meet community Special Authority criteria*

- Tab 50 mg

FLUTAMIDE

- Tab 250 mg

MEGESTROL ACETATE

- Tab 160 mg

OCTREOTIDE**Restricted – LAR (10, 20, 30 mg) presentations***Must meet community Special Authority criteria*

- Inj 50 mcg per ml, 1 ml ampoule
- Inj 100 mcg per ml, 1 ml ampoule
- Inj 500 mcg per ml, 1 ml ampoule
- Inj 10 mg vial
- Inj 20 mg vial
- Inj 30 mg vial

TAMOXIFEN CITRATE

- Tab 10 mg
- Tab 20 mg

Aromatase Inhibitors**ANASTROZOLE**

- Tab 1 mg

EXEMESTANE

- Tab 25 mg

LETROZOLE

- Tab 2.5 mg

Immune Modulators**ANTITHYMOCYTE GLOBULIN (EQUINE)**

- Inj 50 mg per ml, 5 ml ampoule

ANTITHYMOCYTE GLOBULIN (RABBIT)

- Inj 25 mg vial

BACILLUS CALMETTE-GUERIN (BCG)

- Inj 2-8 x 10⁸ CFU vial

INFLIXIMAB**Restricted***Steroid-refractory acute graft vs. host disease of the gut*

- Inj 100 mg vial

PICIBANIL

- Inj 100 mg vial

RITUXIMAB**Restricted***Must meet PCT Special Authority criteria*

- Inj 10 mg per ml, 10 ml vial

- Inj 10 mg per ml, 50 ml vial

TRASTUZUMAB**Restricted***Must meet PCT Special Authority criteria*

- Inj 150 mg vial

- Inj 440 mg vial

Immunosuppressants**AZATHIOPRINE**

- Tab 50 mg
- Inj 50 mg vial

BASILIXIMAB**Restricted***For use in solid organ transplants*

- Inj 20 mg vial

CICLOSPORIN

- Cap 25 mg
- Cap 50 mg
- Cap 100 mg
- Oral liq 100 mg per ml
- Inj 50 mg per ml, 5 ml ampoule

MYCOPHENOLATE MOFETIL**Restricted [oral forms]***Must meet community Special Authority criteria*

- Cap 250 mg
- Tab 500 mg
- Powder for oral liq 1 g per 5 ml
- Inj 500 mg vial

SIROLIMUS

Restricted

Must meet community Special Authority criteria

- Tab 1 mg
- Tab 2 mg
- Oral liq 1 mg per ml

TACROLIMUS

Restricted

Must meet community Special Authority criteria

- Cap 0.5 mg
- Cap 1 mg
- Cap 5 mg
- Inj 5 mg per ml, 1 ml ampoule

Products proposed not to be included

The following products were considered as part of the review of this section, and we are proposing that they not be listed in Part II of Section H at this time. Please note that this would not prevent them from being considered for inclusion at a later date.

- Clofarabine
- Crisantaspase
- Daunorubicin citrate, liposomal
- Mitotane
- Muromonab-CD3
- Pegylated doxorubicin hydrochloride, liposomal
- Plerixafor
- Teniposide
- Topotecan
- Vindesine

We are also proposing that the following products not be included. Please note that for each of these, we are proposing that other presentations or strengths would be included in this section.

- Calcium folinate
 - Inj 1 mg per ml, 50 ml
- Carmustine
 - Implant 7.7 mg
- Fluorouracil sodium
 - Inj 25 mg per ml, 20 ml
- Methotrexate
 - Inj 25 mg per ml, 40 ml

Some of these products are currently included in Part II of Section H, because PHARMAC has established national pricing contracts for them. As part of this proposal PHARMAC would delist the following products from Section H with effect from 1 July 2013:

- Fluorouracil sodium, inj 25 mg per ml, 20 ml (Mayne)
- Methotrexate, inj 25 mg per ml, 40 ml (DBL Methotrexate)

Changes to pharmaceutical cancer treatment (PCT) funding

Through this review process, a number of new PCT listings have been suggested for items that have previously been funded under NPPA (and Cancer EC previously). We are considering these further, and may issue subsequent consultation to implement some or all of these proposals. These include clofarabine, carmustine implant, liposomal daunorubicin, topotecan and crisantaspase.

Biologic agents

Please note that we have considered infliximab and rituximab in previous consultation documents for other indications, such as in rheumatology, dermatology and gastroenterology; the restrictions proposed in this paper should therefore be considered to be in addition to any indications previously consulted upon.

Additional indications have been proposed to us throughout this process, such as in renal medicine; we intend to consider these further over the coming months, and we will be discussing this with relevant parties.

SPECIAL FOODS

Food Modules

Carbohydrate

CARBOHYDRATE SUPPLEMENT

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 7)

Powder 95 g carbohydrate per 100 g, 400 g
{Polycal}

Powder 95 g carbohydrate per 100 g, 368 g
{Moducal}

Fat

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 7)

MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT

Liquid 95 g fat per 100 ml, 500 ml bottle **{MCT Oil}**

Liquid 50 g fat per 100 ml, 250 ml bottle
{Liquigen}

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT

Liquid 50 g fat per 100 ml, 200 ml bottle **{Calogen}**

Liquid 50 g fat per 100 ml, 500 ml bottle **{Calogen}**

Protein

PROTEIN SUPPLEMENT

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 8)

Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can **{Promod}**

Powder 6 g protein per 7 g, 227 g can
{Resource Beneprotein}

Powder 88.5 g protein, 0.5 g carbohydrate and 1.6 g fat per 100 g, 225 g can **{Protifar}**

Other Supplements

BREAST MILK FORTIFIER

Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet **{FM 85}**

Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet **{S-26 Human Milk Fortifier}**

Powder 0.4 g protein and 1.5 g carbohydrate per 2.1 g sachet **{Nutricia Breast Milk Fortifier}**

CARBOHYDRATE AND FAT SUPPLEMENT

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 8)

Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can **{Super Soluble Duocal}**

Food Thickeners

CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN

Powder **{Karicare Food Thickener}**

GUAR GUM

Powder **{Guarcol}**

MAIZE STARCH

Powder **{Resource Thicken Up / Nutilis}**

Standard Feeds

Restricted

Any of the following:

1. For patients with malnutrition, defined as any of the following:
 - 1.1. BMI < 18.5;
 - 1.2. Greater than 10% weight loss in the last 3-6 months; or
 - 1.3. BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
2. For patients who have, or are expected to, eat little or nothing for 5 days;
3. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism;

4. For use pre- and post-surgery;

5. For patients being tube-fed; or

6. For tube-feeding as a transition from intravenous nutrition.

ORAL FEED

Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, 900 g can **{Ensure}**

Powder 18.7 g protein, 54.5 g carbohydrate and 18.9 g fat per 100 g, 900 g can **{Fortisip}**

Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, 900 g can
{Sustagen Hospital Formula}

ORAL FEED 1 KCAL/ML

Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton
{Resource Fruit Beverage}

ORAL FEED 1.5 KCAL/ML

Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml carton **{Fortijuice}**

Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, 237 ml can **{Ensure Plus}**

Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle **{Fortisip}**

Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, 200 ml carton
{Ensure Plus}

Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle
{Fortisip Multi Fibre}

ENTERAL FEED 1 KCAL/ML

Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 500 ml bottle **{Nutrison Standard RTH}**

Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1000 ml bag
{Nutrison Standard RTH}

Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 500 ml bottle **{Nutrison Low Sodium}**

Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1000 ml bag **{Nutrison Low Sodium}**

Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, 250 ml can **{Osmolite}**

Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, 500 ml bottle **{Osmolite RTH}**

Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, 1000 ml bottle **{Osmolite RTH}**

Liquid 4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 250 ml can **{Isosource Standard}**

Liquid 4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 1000 ml bottle **{Isosource Standard RTH}**

Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, 237 ml can **{Jevity}**

Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, 500 ml bottle **{Jevity RTH}**

Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, 1000 ml bottle **{Jevity RTH}**

Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 500 ml bag **{Nutrison Multi Fibre}**

Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag **{Nutrison Multi Fibre}**

ENTERAL FEED 1.5 KCAL/ML

Liquid 6 g protein, 18.5 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1000 ml bag **{Nutrison Energy Multi Fibre}**

Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, 250 ml can **{Ensure Plus HN}**

Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, 1000 ml bag **{Ensure Plus HN RTH}**

Specialised Formulas

Diabetic Products

Restricted

Must meet community Special Authority criteria

LOW-GI ORAL FEED 1 KCAL/ML

Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 250 ml bottle **{Glucerna Select}**

Liquid 6.4 g protein, 9.5 g carbohydrate, 4.7 g fat and 1.2 fibre per 100 ml, 237 ml can **{Resource Diabetic}**

Liquid 4 g protein, 8.8 g carbohydrate, 5.4 g fat and 2.5 g fibre per 100 ml, 200 ml bottle **{Diasip}**

LOW-GI ENTERAL FEED 1 KCAL/ML

Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1000 ml bottle **{Glucerna Select RTH}**

Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1000 ml bottle **{Diason}**

Elemental and Semi-Elemental Products

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 8)

AMINO ACID ORAL FEED

Powder 11.5 g protein, 61.7 g carbohydrate and 0.8 g fat per 80.4 g sachet **{Vivonex T.E.N.}**

AMINO ACID ORAL FEED 0.8 KCAL/ML

Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton **{Elemental 028 Extra}**

PEPTIDE-BASED ORAL FEED

Powder 7.4 g protein, 25.5 g carbohydrate and 12 g fat per 51 g sachet **{Peptide Junior}**

Powder 12.5 g protein, 55.4 g carbohydrate and 3.25 g fat per 79 g sachet **{Vital HN}**

Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can **{Peptamen Junior}**

Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can **{MCT Peptide, MCT Peptide 1+}**

Powder 15.8 g protein, 49.5 g carbohydrate and 4.65 g fat per 76 g sachet **{Alitraq}**

PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML

Liquid 2.8 g protein, 13.7 g carbohydrate and 3.9 g fat per 100 ml, 500 ml bag **{Nutrini Peptisorb}**

Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1000 ml bag **{Nutrison Peptisorb}**

Hepatic Products

Restricted

Must meet community Special Authority criteria

HEPATIC ORAL FEED

Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, 400 g can **{Heparon Junior}**

High Calorie Products

Restricted

Cystic fibrosis

Both of the following:

1. Cystic fibrosis; and
2. Patient has substantially increased metabolic requirements.

Other indications

Both:

1. Any of the following:
 - 1.1. Any condition causing malabsorption; or
 - 1.2. Faltering growth in an infant/child; or
 - 1.3. Increased nutritional requirements; or
 - 1.4. Fluid restricted; and
2. Patient has substantially increased metabolic requirements or is fluid restricted.

ORAL FEED 2 KCAL/ML

Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, 237 ml can **{TwoCal HN}**

ENTERAL FEED 2 KCAL/ML

Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 500 ml bottle
{Nutrison Concentrated}

Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, 100 ml bottle
{TwoCal HN RTH}

High Protein Products

HIGH PROTEIN ORAL FEED 1 KCAL/ML

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 9)

Liquid 10 g protein, 10.3 g carbohydrate and 2.1 g fat per 100 ml, 200 ml bottle **{Fortimel Regular}**

HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML

Restricted

Both:

1. The patient has a high protein requirement; and
2. Any of the following:
 - 2.1. Patient has liver disease; or
 - 2.2. Patient is obese (BMI > 30) and is undergoing surgery; or
 - 2.3. Patient is fluid restricted.

Liquid 6.3 g protein, 14.1 g carbohydrate and 4.9 g fat per 100 ml, 1000 ml bag
{Nutrison Protein Plus}

Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag
{Nutrison Protein Plus Multi Fibre}

Infant Formulas

AMINO ACID FORMULA

Restricted

Must meet community Special Authority criteria

Powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can
{Neocate Advance - vanilla}

Powder 14 g protein, 50 g carbohydrate and 22.1 g fat per 100 g, 400 g can
{Neocate Advance - tropical}

Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can **{Neocate}**

Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, 400 g can **{Neocate Gold}**

Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, 400 g can **{Elecare LCP}**

Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, 400 g can **{Elecare}**

Powder 6 g protein, 31.5 g carbohydrate and 5.88 g fat per 48.5 g sachet **{Vivonex Paediatric}**

Powder 13 g protein, 52.5 g carbohydrate and 24.5 g fat per 100 g, 400 g can **{Neocate LCP}**

EXTENSIVELY HYDROLYSED FORMULA

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 10)

Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can **{Pepti Junior Gold}**

FAT-MODIFIED FORMULA

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 10)

Powder 11.4 g protein, 68 g carbohydrate and 11.8 g fat per 100 g, 400 g can **{Monogen}**

FRUCOSE-BASED FORMULA

Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can **{Galactomin 19}**

LACTOSE-FREE FORMULA

Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can
{S26 Lactose Free}

Powder 1.7 g protein, 7.5 g carbohydrate and 3.7 g fat per 100 ml, 900 g can **{Karicare De-Lact}**

LOW-CALCIUM FORMULA

Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can **{Locasol}**

PRETERM FORMULA

Restricted

For infants born before 33 weeks' gestation or weighing less than 1.5 kg at birth

Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, 100 ml bottle
{S26 LBW Gold RTF}

Liquid 2.3 g protein, 8.6 g carbohydrate, 4.2 g fat per 100 ml, 90 ml bottle **{Pre Nan Gold RTF}**

Liquid 2.5 g protein, 7.6 g carbohydrate and 4.4 g fat per 100 ml, 60 ml bottle
{Karicare Nutriprem}

Powder 1.9 g protein, 7.5 g carbohydrate and 3.9 g fat per 14 g, 400 g can **{S-26 Gold Premgro}**

SOYA FORMULA

Powder 1.8 g protein, 6.6 g carbohydrate and 3.7 g fat per 100 ml, 900 g can
{Karicare Soy All Ages}

Powder 1.8 g protein, 6.9 g carbohydrate and 3.6 g fat per 100 ml, 900 g can **{S26 Soy}**

THICKENED FORMULA

Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can
{Karicare Thickened AR}

Ketogenic Diet Products

Restricted

Must meet community Special Authority criteria

HIGH FAT FORMULA

Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, 300 g can **{Ketocal 3:1}**

Powder 15.25 g protein, 3 g carbohydrate and 73 g fat per 100 g, 300 g can **{Ketocal 4:1}**

Paediatric Products

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 9)

PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML

Liquid 2 g protein, 9.3 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, 500 ml bag **{Nutrini Low Energy Multifibre RTH}**

PAEDIATRIC ORAL FEED 1 KCAL/ML

Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.8 g fibre per 100 ml, 100 ml bottle **{Infatrini}**

Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 200 ml carton **{Pediasure}**

Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 237 ml can **{Pediasure}**

PAEDIATRIC ENTERAL FEED 1 KCAL/ML

Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 500 ml bag **{Pediasure RTH}**

Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag **{Nutrini RTH}**

PAEDIATRIC ORAL FEED 1.5 KCAL/ML

Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle **{Fortini}**

Liquid 3.4 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle **{Fortini Multifibre}**

PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML

Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag **{Nutrini Energy RTH}**

Renal Products

LOW ELECTROLYTE ORAL FEED

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 11)

Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can **{Kindergen}**

LOW ELECTROLYTE ORAL FEED 2 KCAL/ML

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 10)

Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle **{Suplena}**

Liquid 7 g protein, 20.6 g carbohydrate, 9.6 g fat and 1.56 g fibre per 100 ml, 200 ml carton **{Nepro}**

Liquid 7 g protein, 20.6 g carbohydrate, 9.6 g fat and 1.56 g fibre per 100 ml, 500 ml bottle **{Nepro RTH}**

Liquid 7.4 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 237 ml carton **{Novasource Renal}**

Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton **{Renilon 7.5}**

Respiratory Products

Restricted

Must meet community Special Authority criteria (to be amended as noted on page 11)

LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML

Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, 237 ml bottle **{Pulmocare}**

Surgical Products

HIGH ARGININE ORAL FEED 1.4 KCAL/ML

Restricted

Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery

Liquid 7.6 g protein, 18.9 g carbohydrate, 3.9 g fat and 1.4 g fibre per 100 ml, 237 ml carton **{Impact Advanced Recovery}**

Metabolic Products

Restricted

Either:

1. For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
2. Patient has adrenoleukodystrophy; or
3. For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Homocystinuria Products

AMINO ACID FORMULA (WITHOUT METHIONINE)

Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle **{HCU Anamix Junior LQ}**

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can **{HCU Anamix Infant}**

Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can **{XMET Maxamaid}**

Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can **{XMET Maxamum}**

Maple Syrup Urine Disease Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE)

Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle **{MSUD Anamix Junior LQ}**

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can **{MSUD Anamix Infant}**

Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can **{MSUD Maxamaid}**

Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can **{MSUD Maxamum}**

Phenylketonuria Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE)

- Tab 833 mg protein equivalent **{Phlexy-10}**
- Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton **{Easiphen}**
- Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle **{PKU Anamix Junior LQ}**
- Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle **{PKU Lophlex LQ 10 - citrus}**
- Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle **{PKU Lophlex LQ 20 - citrus}**
- Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle **{PKU Lophlex LQ 10 - orange, berry}**
- Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle **{PKU Lophlex LQ 20 - orange, berry}**
- Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet **{Phlexy-10}**
- Powder 8.4 g protein, 9.9 g carbohydrate and 3.9 g fat per 29 g sachet **{Minaphlex}**
- Powder 13 g protein, 54 g carbohydrate and 23 g fat per 100 g, 400 g can **{XP Analog LCP}**
- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can **{PKU Anamix Infant}**
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can **{XP Maxamaid}**
- Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can **{XP Maxamum}**

Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN)

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can **{GA1 Anamix Infant}**
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can **{XLYS Low TRY Maxamaid}**

Isovaleric Acidaemia Products

AMINO ACID FORMULA (WITHOUT LEUCINE)

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can **{IVA Anamix Infant}**
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can **{XLEU Maxamaid}**
- Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can **{XLEU Maxamum}**

Propionic Acidaemia and Methylmalonic Acidaemia Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE)

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 fibre per 100 g, 400 g can **{MMA/PA Anamix Infant}**
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can **{XMTVI Maxamaid}**
- Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can **{XMTVI Maxamum}**

Tyrosinaemia Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE)

- Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 fibre per 100 ml, 125 ml bottle **{TYR Anamix Junior LQ}**
- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 fibre per 100 g, 400 g can **{TYR Anamix Infant}**

- Powder 29 g protein, 38 g carbohydrate and 13.5 g fat per 100 g, 29 g sachet **{TYR Anamix Junior}**
- Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can **{XPHEN, TYR Maxamaid}**

Urea Cycle Disorders Products

AMINO ACID SUPPLEMENT

- Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can **{Dialamine}**
- Powder 79 g protein per 100 g, 200 g can **{Essential Amino Acid Mix}**

X-Linked Adrenoleukodystrophy Products

GLYCEROL TRIERUCATE

Liquid

GLYCEROL TRIOLEATE

Liquid

Products proposed not to be included

The following products were considered as part of the review of this section, and we are proposing that they not be listed in Part II of Section H at this time. Please note that this would not prevent them from being considered for inclusion at a later date.

Fibre supplement **{Stimulance}**

Protein and fat supplement **{Calogen Extra}**

High protein oral feed 1.25 kcal/ml **{Cubitan}**

High protein oral feed 1.6 kcal/ml **{Forticreme}**

High protein oral feed 1.6 kcal/ml **{Forticare}**

Paediatric enteral feed 1 kcal/ml **{Tentrini RTH}**

Paediatric enteral feed 1.5 kcal/ml **{Tentrini Energy RTH, Tentrini Energy Multifibre RTH}**

Oral feed 2.5 kcal/ml **{Scandishake}**

Low electrolyte oral feed 2 kcal/ml **{Renilon 4.0}**

Extensively hydrolysed infant formula **{Alfare}**

Oral feed 1 kcal/ml **{Oral Impact}**

Oral feed 0.5 kcal/ml **{Pre-Op}**

Enteral feed 1 kcal/ml **{Cubison}**

Oral feed 0.15 kcal/ml **{Resource Arginaid}**

Oral feed 1 kcal/ml **{Resource Arginaid Extra}**

Amino acid formula (without phenylalanine) with minerals **{Metabolic Mineral Mixture}**

Oral feed 1 kcal/ml **{Generaid Plus}**

One of these products (Resource Arginaid) is currently included in Part II of Section H, because PHARMAC has established a national pricing contract for it. As part of this proposal PHARMAC would delist it from Section H with effect from 1 July 2013. The applicable national

contracts would be terminated in relation to this product (but would continue in force in relation to any other products) if this proposal is implemented.

We have also considered several supplements for metabolic conditions, such as individual amino acids, and while we are not proposing their inclusion in Section H at this time, we intend to consider these further over the coming months.

Foods for special diets

This list does not include several food items that are subsidised in the community such as low-protein pasta and gluten-free bread mix. It is our intention that these products would be outside the scope of Part II of Section H, and so hospitals would therefore be able to make their own decisions regarding whether these products are used in the preparation of meals for patients with special dietary needs.

Proposed changes to community pharmaceutical funding

As part of this proposal, we are proposing to amend the Special Authority criteria for a number of special foods from 1 July 2013. All changes are in bold

Carbohydrate supplements

The initial Special Authority criteria for carbohydrate supplements would be amended as follows:

Initial application — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Either:

- 1 cystic fibrosis; or
- 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 **for use as a component in a modular formula (not as an additive); or**
- 2 cancer in children; or
- 3 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 4 **faltering growth in an infant/child;**
~~failure to thrive; or~~
~~growth deficiency; or~~
- 5 bronchopulmonary dysplasia; or
- 6 premature and post premature infant; or
- 7 inborn errors of metabolism.

Fat supplements

The initial Special Authority criteria for fat supplements would be amended as follows:

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 **for use as a component in a modular formula (not as an additive); or**
- 2 **faltering growth in an infant/child;**
~~failure to thrive where other high-calorie products are inappropriate or inadequate; or~~
~~growth deficiency; or~~
- 3 bronchopulmonary dysplasia; or
- 4 fat malabsorption; or
- 5 lymphangiectasia; or
- 6 short bowel syndrome; or
- 7 infants with necrotising enterocolitis; or
- 8 biliary atresia; or
- 9 **for use in a ketogenic diet.**

Protein supplements

The initial Special Authority criteria for protein supplements would be amended as follows:

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 **for use as a component in a modular formula (not as an additive); or**
- 2 protein losing enteropathy; or
- 3 high protein needs (eg burns).

Carbohydrate and fat supplement

The initial Special Authority criteria for carbohydrate and fat supplement {Super Soluble Duocal} would be amended as follows:

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner.

Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 infant **or child** aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Infant **or child** aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 **faltering growth; or**
~~failure to thrive; or~~
~~growth deficiency; or~~
 - 2.3 bronchopulmonary dysplasia; or
 - 2.4 premature and post premature infants.

Elemental and semi-elemental products

The initial Special Authority criteria for elemental and semi-elemental products would be amended as follows:

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
~~pancreatitis.~~
- 4 **eosinophilic oesophagitis; or**
- 5 **inflammatory bowel disease.**

High calorie products

The initial Special Authority criteria for high calorie products {Twocal HN, Nutrison Concentrated} would be amended as follows:

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
~~failure to thrive; or~~
 - 1.2 **faltering growth in an infant/child; or**
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

High protein products

The initial Special Authority criteria for high protein products {Fortimel Regular} would be amended as follows:

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

~~Both:~~

~~Anorexia and weight loss; and~~

Either:

- 1 decompensating liver disease without encephalopathy; or
- 2 protein losing gastro-enteropathy.

Paediatric products

The initial Special Authority criteria for paediatric products {Pediasure, Fortini, Nutrini} would be amended as follows:

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
~~failure to thrive; or~~
 - 2.3 **faltering growth in an infant/child; or**
 - 2.4 increased nutritional requirements; or
 - 2.5 **the child is being transitioned from TPN or tube feeding to oral feeding.**

Extensively hydrolysed formula

The initial Special Authority criteria for extensively hydrolysed formula {Pepti Junior Gold} would be amended as follows:

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malabsorption; or
~~Chylous ascite; or~~
~~Chylothorax; or~~
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure.

Fat-modified products

The initial Special Authority criteria for Monogen would be amended as follows:

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

~~Either:~~

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has chylothorax; **or**
- 3 **Modified as a modular feed for adults.**

Renal products

All adult renal products {Suplena, Nepro, Renilon 7.5 and Novasource Renal} would be available under a single Special Authority restriction:

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has acute or chronic renal failure.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

The initial Special Authority criteria for Kindergen would be amended as follows:

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with **acute or** chronic renal failure.

Respiratory products

The initial Special Authority criteria for Pulmocare would be amended as follows:

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia, **defined as a CO₂ value exceeding 55 mmHg.**

VACCINES

Bacterial Vaccines

BACILLUS CALMETTE-GUERIN VACCINE

Restricted

Must meet community funding criteria

Inj 2-8 million CFU per ml vial with diluent

DIPHTHERIA AND TETANUS VACCINE

Restricted

Must meet community funding criteria

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe

DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE

Restricted

Must meet community funding criteria

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe

HAEMOPHILUS INFLUENZAE TYPE B VACCINE

Restricted

Must meet community funding criteria

Inj 10 mcg vial with diluent syringe

MENINGOCOCCAL A, C, Y AND W-135 VACCINE

Restricted

Must meet community funding criteria

Inj 200 mcg vial with diluent

PNEUMOCOCCAL (PCV10) VACCINE

Restricted

Must meet community funding criteria

Inj 16 mcg in 0.5 ml syringe

PNEUMOCOCCAL (PCV13) VACCINE

Restricted

Must meet community funding criteria

Inj 30.8 mcg in 0.5 ml syringe

PNEUMOCOCCAL (PCV23) VACCINE

Restricted

Must meet community funding criteria

Inj 575 mcg in 0.5 ml vial

SALMONELLA TYPHI VACCINE

Restricted

Must meet community funding criteria

Inj 25 mcg in 0.5 ml syringe

Bacterial and Viral Vaccines

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE

Restricted

Must meet community funding criteria

Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D antigen units poliomyelitis virus in 0.5 ml syringe

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE

Restricted

Must meet community funding criteria

Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial

Viral Vaccines

HEPATITIS A VACCINE

Restricted

For use in transplant patients prior to transplant

Inj 720 ELISA units in 0.5 ml syringe

Inj 1440 ELISA units in 1 ml syringe

HEPATITIS B VACCINE

Restricted

Any of the following:

1. Household or sexual contacts of known hepatitis B carriers
2. Children born to mothers who are hepatitis B surface antigen (HBsAg) positive;
2. Dialysis patients;
3. HIV-positive patients; or
4. Hepatitis C positive patients.

Inj 5 mcg in 0.5 ml vial

Inj 10 mcg in 1 ml vial

HUMAN PAPILOMAVIRUS 6, 11, 16 AND 18 VACCINE

Restricted

Any of the following:

1. Women aged between 12 and 19 years old;
2. Male patients aged between 9 and 18 years old with confirmed HIV infection; or
3. Transplant patients prior to transplant.

Inj 120 mcg in 0.5 ml syringe

INFLUENZA VACCINE

Restricted

Must meet community funding criteria

Inj 45 mcg in 0.5 ml syringe

MEASLES, MUMPS AND RUBELLA VACCINE

Restricted

Must meet community funding criteria

Inj 1000 TCID50 measles, 12500 TCID50 mumps
and 1000 TCID50 rubella vial with diluent

POLIOMYELITIS VACCINE

Restricted

Must meet community funding criteria

Inj 80 D-antigen units in 0.5 ml syringe

RABIES VACCINE

Inj 2.5 IU vial with diluent

VARICELLA ZOSTER VACCINE

Restricted

Either:

- 1. For use in transplant patients prior to transplant; or*
- 2. For use in immunosuppressed patients*

Inj 1350 PFU vial with diluent

Inj 2000 PFU vial with diluent

Products proposed not to be included

The following products were considered as part of the review of this section, and we are proposing that they not be listed in Part II of Section H at this time. Please note that this would not prevent them from being considered for inclusion at a later date.

Rotavirus vaccine

Diphtheria toxoid with haemophilus B conjugate vaccine, pertussis vaccine; and tetanus toxoid

Haemophilus B conjugate vaccine with hepatitis B vaccine

Hepatitis A vaccine with hepatitis B vaccine

Tetanus toxoid

VARIOUS

Agents Used in the Treatment of Poisonings

Antidotes

ACETYLCYSTEINE

- Tab eff 200 mg
- Inj 200 mg per ml, 10 ml ampoule
- Inj 200 mg per ml, 30 ml, vial

DIGOXIN IMMUNE FAB

- Inj 38 mg vial *{Digibind}*
- Inj 40 mg vial *{DigiFab}*

ETHANOL, DEHYDRATED

- Inj 100%, 5 ml ampoule

ETHANOL WITH GLUCOSE

- Inj 10% with glucose 5%, 500 ml bag

FLUMAZENIL

- Inj 0.1 mg per ml, 5 ml ampoule

HYDROXOCOBALAMIN

- Inj 2.5 g vial

NALOXONE HYDROCHLORIDE

- Inj 400 mcg per ml, 1 ml ampoule

PRALIDOXIME IODIDE

- Inj 25 mg per ml, 20 ml ampoule

SODIUM NITRITE

- Inj 30 mg per ml, 10 ml ampoule

SODIUM THIOSULFATE

- Inj 250 mg per ml, 10 ml vial

SOYA OIL

- Inj 20%, 500 g bag *{Intralipid}*
- Inj 20%, 500 g bottle *{Intralipid}*

Antitoxins

BOTULISM ANTITOXIN

- Inj 250 ml

DIPHTHERIA ANTITOXIN

- Inj 10,000 iu vial

Antivenoms

RED BACK SPIDER ANTIVENOM

- Inj 500 u vial

SNAKE ANTIVENOM

- Inj 50 ml vial

Removal and Elimination

CHARCOAL

- Oral liq 50 g per 250 ml

DEFERIPRONE

Restricted

Must meet community Special Authority criteria

- Tab 500 mg

- Oral liq 100 mg per ml

DEFERRIOXAMINE MESILATE

- Inj 500 mg vial

DICOBALT EDETATE

- Inj 15 mg per ml, 20 ml ampoule

DIMERCAPROL

- Inj 50 mg per ml, 2 ml ampoule

DIMERCAPTOSUCCINIC ACID

- Cap 100 mg

DISODIUM EDETATE

- Inj 150 mg per ml, 100 ml vial
- Inj 150 mg per ml, 20 ml ampoule
- Inj 150 mg per ml, 20 ml vial

SODIUM CALCIUM EDETATE

- Inj 200 mg per ml, 2.5 ml ampoule
- Inj 200 mg per ml, 5 ml ampoule

Contrast Media

Ionic Vascular Radiocontrast Preparations

IODIXANOL *{Visipaque}*

- Inj 270 mg per ml, 20 ml vial
- Inj 270 mg per ml, 50 ml bottle
- Inj 270 mg per ml, 100 ml bottle
- Inj 320 mg per ml, 20 ml vial
- Inj 320 mg per ml, 50 ml bottle
- Inj 320 mg per ml, 100 ml bottle
- Inj 320 mg per ml, 150 ml bottle
- Inj 320 mg per ml, 200 ml bottle

Non-Ionic Vascular Radiocontrast Preparations

IOHEXOL *{Omnipaque}*

- Inj 240 mg per ml, 50 ml bottle
- Inj 300 mg per ml, 20 ml bottle
- Inj 300 mg per ml, 50 ml bottle
- Inj 300 mg per ml, 100 ml bottle
- Inj 300 mg per ml, 500 ml bottle
- Inj 350 mg per ml, 20 ml bottle
- Inj 350 mg per ml, 50 ml bottle
- Inj 350 mg per ml, 75 ml bottle
- Inj 350 mg per ml, 100 ml bottle
- Inj 350 mg per ml, 200 ml bottle
- Inj 350 mg per ml, 500 ml bottle

IOMEPROL *{Iomeron}*

- Inj 150 mg per ml, 50 ml bottle
- Inj 300 mg per ml, 20 ml vial
- Inj 300 mg per ml, 50 ml bottle
- Inj 300 mg per ml, 100 ml bottle
- Inj 350 mg per ml, 20 ml vial
- Inj 350 mg per ml, 50 ml bottle
- Inj 350 mg per ml, 75 ml bottle
- Inj 350 mg per ml, 100 ml bottle
- Inj 400 mg per ml, 50 ml bottle

IOPROMIDE {Ultravist}

Inj 240 per ml, 50 ml bottle
 Inj 300 per ml, 20 ml vial
 Inj 300 per ml, 50 ml bottle
 Inj 300 per ml, 100 ml bottle
 Inj 370 per ml, 30 ml vial
 Inj 370 per ml, 50 ml bottle
 Inj 370 per ml, 100 ml bottle
 Inj 370 per ml, 200 ml bottle

IOTROLAN {Isovist}

Inj 240 mg per ml, 10 ml vial

Oral Radiocontrast Preparations**MEGLUMINE AMIDOTRIZOATE WITH SODIUM AMIDOTRIZOATE {Gastrografin}**

Oral liq 370 mg per ml with sodium amidotrizoate
 100 mg per ml, 100 ml

SODIUM DIATRIZOATE {Ioscan}

Oral liq 370 mg per ml, 10 ml

Urological Radiocontrast Preparations**MEGLUMINE AMIDOTRIZOATE WITH SODIUM AMIDOTRIZOATE {Urografin}**

Inj 146 mg with sodium amidotrizoate 40 mg per
 ml, 250 ml bottle
 Inj 370 mg with sodium amidotrizoate 100 mg per,
 50 ml bottle

Extraceullular Fluid Gadolinium Chelates**GADOBUTROL {Gadovist}**

Inj 1 mmol per ml, 7.5 ml syringe
 Inj 1 mmol per ml, 15 ml vial

GADODIAMIDE {Omniscan}

Inj 287 mg per ml, 5 ml vial
 Inj 287 mg per ml, 10 ml vial
 Inj 287 mg per ml, 15 ml vial
 Inj 287 mg per ml, 20 ml vial

GADOTERIC ACID {Dotarem}

Inj 0.5 mmol per ml, 5 ml bottle
 Inj 0.5 mmol per ml, 10 ml bottle
 Inj 0.5 mmol per ml, 20 ml bottle

MEGLUMINE GADOPENTATE {Magnevist}

Inj 469 mg per ml, 10 ml vial
 Inj 469 mg per ml, 15 ml vial
 Inj 469 mg per ml, 20 ml vial

Organ-Specific Gadolinium Chelates**GADOBENIC ACID {Multihance}**

Inj 334 mg per ml, 10 ml vial
 Inj 334 mg per ml, 20 ml vial

GADOXETATE DISODIUM {Primovist}

Inj 181 mg per ml, 10 ml syringe

Other Contrast Media**BARIUM SULPHATE**

Oral liq 1 mg per ml {Volumen}
 Oral liq 2.2 mg per g {CT Plus+}
 Oral liq 13 mg per ml {Readi-Cat}
 Oral liq 21 mg per ml {Readi-Cat 2}
 Oral liq 130 mg per ml {Entero Vu}
 Oral liq 400 mg per ml
 {Tagitol V, Varibar Honey, Varibar Nectar}
 Oral liq 1250 mg per ml {Liquibar}
 Liq 1000 mg per ml {Liquid Polibar}
 Eosophageal cream 30 mg per g {Esopho-Cat}
 Eosophageal cream 600 mg per g {E-Z-Paste}
 Eosophageal paste 400 mg per ml
 {Varibar Pudding}
 Enema 1250 mg per ml {Liquibar Enema}
 Powder for oral liq 22.1 g {E-Z-Cat Dry}
 Powder for oral liq 100 g {Entero Vu}
 Powder for oral liq 148 g {Varibar Thin Liquid}
 Powder for oral liq 300 g {X-Opaque-HD}
 Powder for oral liq 340 g {E-Z-HD}

Powder for oral liq 10,000 g {E-Z-Paque}

Powder for enema 397 g {ACB-Polibar}

CITRIC ACID WITH SODIUM BICARBONATE

Powder 382.2 mg per g with sodium bicarbonate
 551.3 mg per g, 4 g sachet {E-Z-Gas II}

IODISED OIL

Inj 480 mg per ml, 10 ml ampoule

PHENOL WITH IOXAGLIC ACID

Inj 12%, 10 ml ampoule

Diagnostic Agents**ARGININE**

Inj 50 mg per ml, 500 ml bottle
 Inj 100 mg per ml, 300 ml bottle

HISTAMINE ACID PHOSPHATE

Nebuliser soln 0.6%, 10 ml vial
 Nebuliser soln 2.5%, 10 ml vial
 Nebuliser soln 5%, 10 ml vial

SECRETIN PENTAHYDROCHLORIDE

Inj 100 u ampoule

TUBERCULIN, PURIFIED PROTEIN DERIVATIVE

Inj 10 TIU per 0.1 ml, 1 ml vial

Diagnostic Dyes**BONNEY'S BLUE DYE**

Soln

FLUORESCHEIN SODIUM

Inj 10%, 5 ml vial

INDIGO CARMINE

Inj 4 mg per ml, 5 ml ampoule
 Inj 8 mg per ml, 5 ml ampoule

INDOCYANINE GREEN

Inj 25 mg vial

METHYLTHIONINIUM CHLORIDE

Inj 10 mg per ml, 5 ml ampoule
 Inj 10 mg per ml, 10 ml ampoule

PATENT BLUE V

Inj 2.5%, 2 ml ampoule

Irrigation Solutions

CHLORHEXIDINE

Irrigation soln 0.1%, 30 ml ampoule
Irrigation soln 0.02%, 100 ml ampoule
Irrigation soln 0.02%, 500 ml ampoule
Irrigation soln 0.05%, 100 ml ampoule
Irrigation soln 0.05%, 500 ml ampoule
Irrigation soln 0.1%, 100 ml ampoule
Irrigation soln 0.5%, 500 ml ampoule

CHLORHEXIDINE WITH CETRIMIDE

Irrigation soln 0.015% with cetrimide 0.15%, 30 ml
Irrigation soln 0.015% with cetrimide 0.15%,
100 ml
Irrigation soln 0.015% with cetrimide 0.15%,
500 ml
Irrigation soln 0.015% with cetrimide 0.15%,
1000 ml
Irrigation soln 0.05% with cetrimide 0.5%, 100 ml
Irrigation soln 0.05% with cetrimide 0.5%, 500 ml
Irrigation soln 0.1% with cetrimide 1%, 100 ml
Irrigation soln 0.1% with cetrimide 1%, 500 ml

GLYCINE

Irrigation soln 1.5%, 2000 ml
Irrigation soln 1.5%, 3000 ml

SODIUM CHLORIDE

Irrigation soln 0.9%, 30 ml
Irrigation soln 0.9%, 100 ml
Irrigation soln 0.9%, 500 ml
Irrigation soln 0.9%, 1000 ml
Irrigation soln 0.9%, 2,000 ml
Irrigation soln 0.9%, 3,000 ml

WATER

Irrigation soln, 100 ml

Irrigation soln, 500 ml
Irrigation soln, 1000 ml
Irrigation soln, 2000 ml

Surgical Preparations

BISMUTH SUBNITRATE AND IODOFORM PARAFFIN

Paste

DIMETHYL SULFOXIDE

Soln 50%

PHENOL

Inj 6%, 10 ml ampoule

SODIUM HYALURONATE

Restricted - otolaryngologists

Inj 20 mg per ml, 1 ml syringe **{Restylane,
Restylane Perlane}**

TROMETAMOL

Inj 18 g per 500 ml bottle

Cardioplegia Solutions

ELECTROLYTES

Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2
mmol/l calcium, 16 mmol/l magnesium and 160
mmol/l chloride, 1000 ml bag

{Cardioplegia Solution AHB7832}

Inj citric acid 0.07973 mg per ml, sodium
phosphate 0.06119 mg per ml, potassium
chloride 2.181 mg per ml, sodium chloride 1.788
mg ml, sodium citrate 0.6412 mg per ml and
trometamol 5.9 mg per ml, 523 ml bag

{Cardioplegia Base Solution}

Inj aspartic acid 8.481 mg per ml, citric acid 0.8188
mg per ml, glutamic acid 9.375 mg per ml,
sodium phosphate 0.6285 mg per ml, potassium
chloride 2.5 mg per ml, sodium citrate 6.585 mg
per ml, sodium hydroxide 5.133 mg per ml and
trometamol 9.097 mg per ml, 527 ml bag

{Cardioplegia Enriched Solution}

Inj aspartic acid 10.43 mg per ml, citric acid
0.22476 mg per ml, glutamic acid 11.53 mg per

ml, sodium phosphate 0.1725 mg per ml,
potassium chloride 2.15211 mg per ml, sodium
citrate 1.80768 mg per ml, sodium hydroxide
6.31 mg per ml and trometamol 11.2369 mg per
ml, 364 ml bag

{Cardioplegia Enriched Paediatric Solution}

Inj 143 mmol/L sodium, 16 mmol/L potassium, 16
mmol/L magnesium and 1.2 mmol/L calcium,
1000 ml bag

{Cardioplegia Electrolyte Solution}

Products proposed not to be included

The following products were considered as part of the review of this section, and we are proposing that they not be listed in Part II of Section H at this time. Please note that this would not prevent them from being considered for inclusion at a later date.

Deferasirox

Fuller's earth

Glucarpidase (carboxypeptidase G2)

Ipecacuanha

Sincalide

We are also proposing that the following products not be included. Please note that for each of these, we are proposing that other presentations or strengths would be included in this section.

Acetylcysteine

Tab eff 600 mg

Charcoal

Tab 300 mg

Ethanol

Liq 96%

Ethanol, dehydrated

Inj 100%, 20 ml

Naloxone hydrochloride

Inj 400 µg per ml, 2 ml pre-filled syringe

Glucarpidase

As part of this proposal, we have not proposed that glucarpidase (carboxypeptidase G2) be included in Section H at this time, although we are aware that there has been some use of this pharmaceutical in DHB hospitals recently. We intend to review this product over the coming months, which will include seeking further clinical advice.

Contrast media

We have included a range of products under the “Non-Ionic Vascular Radiocontrast Preparations” heading, as Hospital Supply Status does not currently apply to a product in this category. However, PHARMAC expects to initiate a competitive process for Hospital Supply Status within this category of products in the coming months, so it is possible that this list may be revised in the near future.